BridgeBio Pharma BBIO Payment-in-kind interest
Payment-in-kind interest at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:PaidInKindInterest.
The official record: BridgeBio Pharma’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's payment-in-kind interest.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's payment-in-kind interest?
- BridgeBio Pharma (BBIO) reported payment-in-kind interest of $0 in Q4 2025.
- What is the long-term trend for BridgeBio Pharma's payment-in-kind interest?
- Over 2 years (2023 to 2025), BridgeBio Pharma's payment-in-kind interest has grown at a -100.0% compound annual growth rate (CAGR), from $10.21M to $0.
- What does payment-in-kind interest mean?
- Interest costs paid by issuing more debt or equity instead of cash.
- How do you interpret payment-in-kind interest?
- An increase suggests the company is deferring cash interest obligations, which may signal liquidity constraints or a strategic choice to preserve cash for R&D.
- How does payment-in-kind interest compare across companies?
- Often seen in high-growth biotech companies utilizing complex financing structures to fund long-term clinical trials.